EUVIMEDEUVIMED entdecken
Editorial

Bridging the Gap — Translating AI in Pathology into Clinical Impact

Fang-Yi Su iD, Eliana Marostica iD, Xiyue Wang iD, Sen Yang iD, Jung-Hsien Chiang iD, Shuji Ogino iD, Jeffrey A Golden iD, Jakob Nikolas Kather iD, Ying Qiu iD, Dong Chen iD, Stuart Schnitt iD, Kun-Hsing Yu iD

NEJM AI · 23.07.2026 · 3 (8)

DOI: 10.1056/aip2600029 ↗

Kurz gefasst

Editorial in der Zeitschrift NEJM AI, erschienen am 23.07.2026. Verfasst von Fang-Yi Su und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Artificial Intelligence, Pathology, Translational Research, Biomedical. Die Arbeit nennt 70 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractHematoxylin and eosin-stained tissue analysis has remained the global foundation of diagnostic pathology since the 19th century, and recent advances in artificial intelligence (AI) now enable the extraction of clinical and molecular insights from routine images. Yet only 5 of the 1430 AI- and/or machine learning-enabled medical devices cleared by the U.S. Food and Drug Administration are modern pathology AI tools based on whole-slide images, whereas 1094 are classified in the radiology category. Furthermore, only approximately 4% of U.S. slide volume is currently read digitally. We argue that this disconnect reflects a hierarchy of barriers to clinical impact: foundational infrastructure and economic hurdles, postdigitization challenges related to sample variability and clinician trust, an underdeveloped implementation and governance pathway, and persistent equity gaps in low- and middle-income settings. Against this backdrop, two near- and medium-term translational pathways stand out: AI as a digital copilot for clinical evaluation and AI-enabled clinical trial design. Together, these approaches offer measurable workflow and trial-enabling benefits, with the potential to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligencePathologyTranslational Research, BiomedicalHumansUnited States

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA.
  • Ant Group, Sunnyvale, CA, USA.
  • Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan, Taiwan.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

ORCID-Profile: Fang-Yi Su, Eliana Marostica, Xiyue Wang, Sen Yang, Jung-Hsien Chiang, Shuji Ogino, Jeffrey A Golden, Jakob Nikolas Kather, Ying Qiu, Dong Chen, Stuart Schnitt, Kun-Hsing Yu

Zitieren

APA

Su, F. Y., Marostica, E., Wang, X., Yang, S., Chiang, J. H., Ogino, S., Golden, J. A., Kather, J. N., Qiu, Y., Chen, D., Schnitt, S., & Yu, K. H. (2026). Bridging the Gap — Translating AI in Pathology into Clinical Impact. NEJM AI, 3(8). https://doi.org/10.1056/aip2600029

Vancouver

Su FY, Marostica E, Wang X, Yang S, Chiang JH, Ogino S, et al. Bridging the Gap — Translating AI in Pathology into Clinical Impact. NEJM AI. 2026;3(8). doi:10.1056/aip2600029

BibTeX
@article{Su2026,
  author = {Su, Fang-Yi and Marostica, Eliana and Wang, Xiyue and Yang, Sen and Chiang, Jung-Hsien and Ogino, Shuji and Golden, Jeffrey A and Kather, Jakob Nikolas and Qiu, Ying and Chen, Dong and Schnitt, Stuart and Yu, Kun-Hsing},
  title = {Bridging the Gap — Translating AI in Pathology into Clinical Impact},
  journal = {NEJM AI},
  year = {2026},
  volume = {3},
  number = {8},
  doi = {10.1056/aip2600029}
}
Kostenlos starten →